Description
The debate highlighted focused ultrasound as most feasible but didn’t resolve critical dosing parameters. The temporal window for BBB opening and precise spatial targeting requirements remain undefined, yet these parameters will determine therapeutic index and clinical viability.
Source: Debate session sess_sda-2026-04-01-gap-008 (Analysis: sda-2026-04-01-gap-008)
Resolution criteria
Resolved when a parametric MRI study in a rodent BBB model (FUS + microbubbles, n >= 8 per group) maps BBB permeability (DCE-MRI, Ktrans) across a full duration/frequency matrix (1-60 min opening x 3 acoustic pressures) and links each condition to: (a) tracer leakage volume (IgG staining, mm3), (b) neuronal viability (NeuN+ counts in targeted region >= 95% of sham), and © therapeutic agent CNS bioavailability (LC-MS/MS on brain homogenate, >=3-fold increase vs non-FUS control). The study must establish a safety-efficacy frontier curve. Deliverable: raw DCE-MRI DICOM data in TCIA; SciDEX KG node ‘FUS_BBB_window’ created with quantitative safety-efficacy bounds and evidence_strength >= 0.75.